Merck Presents Data Evaluating Pembrolizumab As Initial Therapy At ASCO 2014

June 2, 2014 12:07 PM

16 0

Merck (MRK: Quote), known as MSD outside the U.S. and Canada, revealed the first presentation of data assessing pembrolizumab (MK-3475), Merck's investigational anti-PD-1 antibody, as initial therapy in patients with PD-L1 positive, advanced non-small cell lung cancer or NSCLC. In previously-untreated patients, the objective response rate or ORR with pembrolizumab as a single-agent was 47 percent by investigator-assessed, immune-related response criteria (irRC) and 26 percent by centrally evaluated RECIST v1.1 (Response Evaluation Criteria in Solid Tumors).

In evaluable patients who had measurable disease with one post baseline scan, 80 percent showed tumor shrinkage as measured by centrally evaluated RECIST criteria, the company noted. The median duration of response has not been reached, with few patients continuing on treatment with pembrolizumab as...

Read more

To category page